Conflicts of interests
|
|
- Abigayle Greene
- 5 years ago
- Views:
Transcription
1 Update in Interventional Cardiology for the Internist Transcatheter valve therapies Dr Vaikom S Mahadevan Director of Structural and Adult Congenital Interventions William W Parmley Endowed Chair in Cardiology Associate Professor of Medicine University of California, San Francisco Conflicts of interests Proctor for Melody Medtronic pulmonary valve - Europe Proctor for Edwards Sapien pulmonic valve - Europe Proctor for Edwards Sapien TF aortic valve USA and Europe Will mention about unlicensed indications for transcatheter valves What valves are currently available Pulmonic valve implantation - Melody valve Medtronic - PMA approval - Edwards Sapien valve - Edwards Life Sciences - Not approved Aortic valve implantation - Edwards Sapien valve - Approved - Corevalve Medtronic - Approved - St Jude s, Boston Scientific, Direct flow valve As part of studies Transcatheter aortic valve Replacement To offer patients with severe AS who are inoperable or very high risk for surgery, a treatment option 1
2 Simplified decision tree for patients considered for percutaneous aortic valve placement. Suitable candidates for THV High Risk Patients Age No absolute age limits Combination of several commorbidities (Renal, respiratory failure, LV dysfunction ) Contra indication to surgery (Porcelain Aorta, chest radiation, ) Not too frail or too much debility Frederick G.P. Welt et al. Circulation. 2011;124: TA, TAo or TF technically feasible Copyright American Heart Association, Inc. All rights reserved. Yes TF (n = 492) 1:1 Randomization TF AVR TAVI vs (Control) (n = 244) (n = 248) PARTNER Study Design Severe Symptomatic Aortic Stenosis Yes Cohort A n = 699 Assessment Transfemoral Access No TA (n = 207) 1:1 Randomization TA AVR TAVI vs (Control) (n = 104) (n = 103) Primary Endpoint: All-Cause Mortality (1 yr) (Non-inferiority) Assessment Operability 2 Cohorts Individually Cohort Powered A (N = 1,057) Yes No Cohort B n = 358 Assessment Transfemoral Access 1:1 Randomization Standard TF Therapy TAVI vs (Control) (n = 179) (n = 179) No Not in Study Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority) Co-Primary Endpoint: Composite of All-Cause Mortality and Repeat Hospitalization (Superiority) All-Cause Mortality, % No. at Risk Edwards THV Standard Therapy 20% Absolute Reduction in all cause Mortality at 1 Year at 1 yr = 20.0% NNT = 5.0 pts 50.7% 30.7% Months Standard Therapy Edwards THV HR [95% CI] = 0.55 [0.40, 0.74] P (log rank) <
3 All cause and CVS Mortality Rate at 30 days and 1 year 50 Survival with TAVR and AVR Mortality, % TAVI (n = 179), 30 Days, 5 All-Cause Standard Rx (n = 179), 30 Days, 2.8 p =.001 TAVI (n = 179), 1 Year, 30.7 Standard Rx (n = 179), 1 Year, 49.7 Column1, 30 Days, 4.5 Cardiovascular Column2, 30 Days, 1.7 Column1, 1 Year, 19.6 p <.001 Column2, 1 Year, 41.9 Mortality, % % 24.2% AVR HR [95% CI] = 0.93 [0.71, 1.22] P (log rank) =.62 p =.41 p =.22 Edwards THV (n = 179) Standard Therapy (n = 179) No. at Risk Edwards THV AVR Months Transfemoral, Transapical Approach / Transaortic approach Annulus Measurement mm Vessels cannot be too Tortuous No large Ischaemic Area Coronary Angiogram Access to the aortic valve 3
4 Transfemoral route General anaesthesia and TEE guidance Need bilateral femoral arterial access and one femoral venous access for temporary pacing wire With ICE support could be done without GA Transapical / Transaortic route General anaesthesia and TOE guidance Cardiac apical / aortic access by cardiac surgeon Femoral venous access for pacing Arterial access for angiography Techniques for measurement of aortic annulus by CT Minimum and maximum diameters and average the mean Area derived diameter D = 2 X (A/ π ) Circumference derived diameter D = C/π Based on TEE 4
5 An example of a TAVR referral 88 year old male History of prostate problems Found to have a large bowel lesion needing surgery On investigation found to have severe AS Raised STS / Euroscore Good iliac and femorals and no major coronary disease Proceeded to TF TAVI Need to minimise valve / paravalvular leak Sometimes post dilatation is required with the same balloon or a different balloon In case of significant central leak a further valve implant is required Valve - in valve implant The Sapien 3 valve has decreased para leak significantly Transaortic approach Increasingly used in patients not suitable for TF approach but high risk with TA Includes those with impaired LV function Direct aortic approach using mini sternotomy Valve delivered using transapical delivery system TF Groin management is now percutaneous Given smaller sheath sizes percutaneous groin access site management Usually 2 / 3proglides sutures predeployed Sheath removal in the cath lab with tightening of predeployed perclose sutures Immediate hemostasis and check angio via contralateral side to confirm 5
6 Edwards SAPIEN 3 Transcatheter Heart Valve The 14 French esheath Sapien 3 implant via Tao route Octagenarian male with severe AS Multiple co-morbidities with severe PVD Moderate LV dysfunction Elected for Sapien 3 implant via Tao route Home on day 5 Objective: Primary Endpoint: Secondary Endpoints: Organization: Follow-Up: Sapien 3 trial The SAPIEN 3 Trial To assess the safety and efficacy of the Edwards SAPIEN 3 Transcatheter Heart Valve (THV) in high- and intermediate-risk patients who are eligible for surgical aortic valve replacement All-cause mortality of the valve-implant population at 30 days post-index procedure Technical success, safety and efficacy endpoints, echocardiographic endpoints Steering Committee, Clinical Events Committee (VARC 2), Echo Core Lab and CT Core Lab 30 days, 1 year, and annually for 5 years This analysis from The SAPIEN 3 Trial presents the 30-day outcomes of the first 150 patients who received TAVI with the Edwards SAPIEN 3 THV. 6
7 Methods Baseline Characteristics (1) The SAPIEN 3 Trial Study Design Prospective, multicenter, non-randomized study Number of Patients 150 (TF [transfemoral] = 96, TAA [transapical / transaortic] = 54) 50 high-risk patients & 100 high-risk or intermediate-risk patients Patient Selection High-risk: STS score 8 or Logistic EuroSCORE 15 Intermediate-risk: STS score 4 to < 8 or Logistic EuroSCORE 10 to < 15 Enrollment Period January 2013 to November 2013 Study Centers 16 sites in Europe and Canada Access Approach Transfemoral, transapical, or transaortic access, as determined by the Heart Team Operability Risk Assessment AT* PATIENTS (N = 150) Age (Years) 83.6 ± 5.0 Female 81 (54.0%) NYHA III/IV 130 (86.7%) Severe Pulmonary Hypertension 10 (6.7%) Severely Impaired Pulmonary Function Contradicting Surgery 8 (5.3%) Hostile Chest 3 (2.0%) Severe Liver Disease / Cirrhosis 2 (1.3%) Frailty Index VARC-2 (continuous) 1.3 ± 0.9 Patients with 1 or More Risk Factors 147 (98.0%) Non-Cardiac Conditions AT* PATIENTS (N = 150) Renal Insufficiency 60 (40.0%) Diabetes 48 (32.0%) Anemia 46 (30.7%) Pulmonary Disease COPD 40 (26.7%) Cancer 32 (21.3%) Echo Parameters AT* PATIENTS (N = 150) Effective Orifice Area (cm 2 ) 0.6 ± 0.2 Mean Gradient (mm Hg) 45.3 ± 14.3 LV Ejection Fraction (LVEF) (%) 56.3 ± 9.2 Mitral Regurgitation (Moderate to Severe) Annular Diameter (TEE - mean) (mm) 26 (22.4%) 23.2 ± 2.3 * AT, as-treated. Procedural Characteristics (1) Procedural Characteristics (2) A C C E S S A P P R O A C H ( % ) V A LV E S I Z E ( % ) Variable TF PATIENTS (N = 96) Variable ALL PATIENTS (N = 150) Femoral Access/Anesthesia General 63.5% Conscious Sedation 36.5% Femoral Access/Closure Percutaneous/Closure Device 95.8% Procedural Outcomes Correct Placement at Intended Site 149 (99.3%) Post-dilatation 5 (3.3%) Technical Success* 94.0% Procedural Events Conversion to Conventional Surgery 1 (0.7%) Surgical 4.2% Patient Required ECMO 1 (0.7%) Coronary Obstruction 0 (0.0%) Valve-in-Valve 0 (0.0%) TF TAA 23 mm 26 mm 29 mm Note: Limited14F esheath availability during initial patient enrollment period. The 29 mm valve was introduced later in the trial. Due to a low rate of paravalvular leak a strategy of minimal oversizing evolved. * No procedural mortality, correct positioning, and only one valve implanted. 7
8 Clinical Outcomes at 30 Days (1) Clinical Improvement at 30 Days Clinical Outcome TF (N = 96) EVENT RATE IN THE AT POPULATION # PATIENTS (KM %) TAA (N = 54) Overall (N = 150) All-Cause Mortality 2 (2.1%) 6 (11.1%) 8 (5.3%) Cardiac Mortality 2 (2.1%) 5 (9.3%) 7 (4.7%) All-Stroke* 1 (1.0%) 3 (5.6%) 4 (2.7%) Disabling Stroke 0 (0.0%) 0 (0.0%) 0 (0.0%) Major Vascular Complication 5 (5.2%) 4 (7.4%) 9 (6.0%) Major Bleeding 19 (19.8%) 11 (20.4%) 30 (20.0%) Life-Threatening Bleeding 2 (2.1%) 3 (5.6%) 5 (3.3%) Rehospitalization 0 (0.0%) 0 (0.0%) 0 (0.0%) Primary Endpoint TF (N = 95) EVENT RATE IN THE VI POPULATION # PATIENTS (KM %) TAA (N = 54) Overall (N = 149) All-Cause Mortality 1 (1.1%) 6 (11.1%) 7 (4.7%) 100% 80% 60% 40% 20% 0% N Y H A C L A S S A N G I N A C C S C L A S S I II III IV None I II III IV p < p = % 1.3% 100% 8.7% 5.9% 9.3% 13.4% 80% 45.2% 10.0% 60% 78.0% 40% 66.0% 48.2% 20% 13.3% 0% Baseline 30 Days Baseline 0.8% 2.2% 11.9% 85.1% 30 Days N = 150 N = 135 N = 150 N = 134 VI, valve implant = all enrolled patients who received a SAPIEN 3 implant, and retain the valve upon leaving the cath lab * Severity of the one TF stroke unknown. Rehospitaliza on for for valve-related symptom or worsening of congestive heart failure. Echocardiographic Data at 30 Days Improvement in Quality of Life at 30 Days T O T A L A R ( N = ) P A R A V A L V U L A R A R ( N = ) VA S E Q - 5 D 6 - M I N U T E W A L K T E S T None/Trace Mild Moderate Severe None/Trace Mild Moderate Severe 100% 80% 60% 2.6% 5.1% 3.4% 28.2% 15.4% 23.9% 100% 80% 60% 2.6% 5.1% 3.4% 28.6% 15.4% 24.1% VAS Score p < p = * Meters * 40% 69.2% 79.5% 72.6% 40% 68.8% 79.5% 72.4% % 20% 20 Baseline 30 Days 50 Baseline 30 Days 0% TF TAA Overall N = 78 N = 39 0% TF TAA Overall N = 117 N = 77 N = 39 N = 116 N = 146 N = 127 N = 76 N = 76 VAS, Visual Analogue Scale. * p-values from paired t-test baseline vs follow-up. 8
9 Conclusions - The SAPIEN 3 Trial Outcomes at 30 days were excellent. TF SAPIEN 3 implantation was associated with a very low mortality of 2.1%, stroke of 1.0%, and very few access-site complications. TF implantation was associated with a very low mortality of 1.1% in the valve implant population. 99.3% of valves were implanted at the intended location - due to precise SAPIEN 3 positioning. 96.6% of patients had mild PVL. There was no severe PVL. Post-implant maneuvers were rarely needed despite reduced oversizing - Procedural post-dilatation (3.3%), valve-in-valve implants (0%) The SAPIEN 3 THV may enable treatment of intermediate-risk patients with aortic stenosis. CoreValve Evolut R System Recaptureable valve and delivery catheter with loading system 23mm Transcatheter Valve Supra-annular design Catheter Delivery System 14Fr-equivalent profile Loading System Evolut R 23 mm CE Approved CoreValve Evolut R Family Evolut R 26 & 29 mm Exclusively for Clinical Investigations Evolut R 3X mm Under Development EnVeo R Delivery Catheter Designed for 1 st Time Positioning Accuracy with Option to Fully Recapture & Reposition * Capsule Flare Nitinol Reinforced 23 mm 26 mm 29 mm 3x mm 1:1 response Self-centering Annulus Size (mm) Nitinol capsule with flare and flexible catheter enable uniform, controlled valve expansion and self-centering 9
10 Indicated for Valve-in-Valve Supra-Annular Design Maximizes Blood Flow Over 25% larger potential orifice area 1 Low Rates of Patient Prosthesis Mismatch Low Post-Procedural Gradients 1. Medtronic data on file. Bench testing comparison between CoreValve and Sapien XT in surgical bioprosthesis. Bench test comparison to Sapien XT, CoreValve device has a 25% larger potential orifice area when implanted in degenerated surgical bioprosthesis. 2. Dvir D, Webb JG, Bleiziffer S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014;312(2): doi: /jama CE Approval is for CoreValve Evolut R 23mm. Pulmonic valve - Device Rationale To reduce the total number of surgeries over the patient s lifetime by postponing time to surgery, while restoring pulmonic function Option to intervene earlier, providing better outcomes for patients while avoiding surgical complications With Pulmonary Stenosis Tetralogy of Fallot Surgical correction of outflow tract non-conduit ~ 85% of all RVOT Pts. With Pulmonary Atresia Anomalies of the RVOT Truncus Arteriosus Transposition Great Arteries ~ 15% 0f RVOT Patients Estimated at 20.1% of all CHD Patients Others RV PA Conduit RV PA Conduit RV PA Conduit RV PA conduit Virtually all patient will require future procedure(s) to replace the conduit and / or pulmonary valve 10
11 Melody Transcatheter Pulmonary Valve Selection Criteria 18mm Contegra bovine jugular vein with valve segment NuMed Platinum Iridium Stent 28 mm length Crimped down to 6mm, re-expanded 18mm up to 22mm Objective evidence of conduit dysfunction - Moderate or severe regurgitation - Right ventricular outflow obstruction Clinical indication for surgical intervention Free PR with progressive or moderate-severe RV dilatation / significant TR Arrythmia or decreasing ET 23 year old with d TGA, VSD and aortic coarctation repair Coarctation repair with PA banding shortly after birth 10 months Arterial switch with debanding of PA and Dacron conduit to elongate PA trunk 2 years RV- PA conduit replacement with 20mm homograft 12 years Tricuspid valve repair and 19mm homograft in pulmonary position Developed progressive exertional dyspnoea and increasing RV pressures Underwent catheterisation and RV pressures greater than 2/3 rd Systemic. Conduit very adherent to sternum Underwent balloon dilation with 18mm balloon with good effect Increasing RV systolic pressure and dyspnoea, underwent stenting of conduit with 3.9cms uncovered stent on 18mm Cristal wire was used for support to deliver the stent using 11 Fr Mullins sheath 11
12 Use of TAVR in other positions Not licenced for routine use Used usually as valve in valve in tricuspid and mitral positions Transcatheter Tricuspid valve implant No licensed valve currently Used for valve in valve implant Inverted TAVI valves 38 year old female Ebstein s anamoly 14 years ago Prosthetic valve TVR Failed prosthesis replaced with bioprosthesis 12 years ago 31mm Sorin Increasing SOB with mixed valve lesion Clinical findings Transthoracic echo revealed significant tricuspid stenosis and regurgitation Reduced exercise tolerance with reduction in peak VO2 maximum Significant RA dilatation and preserved right ventricular systolic function Mean RA pressure of 19mm Hg Mitral valve in valve Not licenced for routine clinical use Useful when there is significant disease of mitral prosthesis and surgical risks are high Can be done transapical or transeptal Can also be done in certain valve ring repairs 12
13 Mitral valve in valve 28 year old female Mitral endocarditis aged 21 with severe MR R hemiplegia with significant residual deficit Two successful pregnancies Severe bioprosthetic valve stenosis with symptoms Does not want further surgery / mechanical valve. ICE in TAVR Avoids the need for GA Via RFV using 8 or 10Fr sheath Now 3D ICE is available However sweep is low but newer systems are in progress Valve annular measurements can be made 13
Conflicts of interests
Update in Interventional Cardiology for the Internist Transcatheter valve therapies Dr Vaikom S Mahadevan Director of Structural and Adult Congenital Interventions William W Parmley Endowed Chair in Cardiology
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationCIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationTAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre
TAVI: The Real Deal? Marc Pelletier, MD Head, Department of Cardiac Surgery New Brunswick Heart Centre Disclosure St. Jude Medical: Consultant and Proctor Edwards Lifesciences: Proctor Medtronic: Research
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationTRANSCATHETER REPLACEMENT OF THE PULMONARY VALVE (PPVI)
TRANSCATHETER REPLACEMENT OF THE PULMONARY VALVE (PPVI) BASIL D. THANOPOULOS MD, PhD Director Interventional Cardiology of CHD Euroclinic ATHENS - GREECE TRANSCATHETER REPLACEMENT OF THE PULMONARY VALVE
More informationTHE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON
THE PERCUTANEOUS MANAGEMENT OF VALVULAR HEART DISEASE DR JOHN RAWLINS CONSULTANT INTERVENTIONAL CARDIOLOGIST UNIVERSITY HOSPITAL SOUTHAMPTON INTRODUCTION History of heart valve intervention Current indications
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationEdwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationTAVI: Present and Future Perspective
TAVI: Present and Future Perspective Igor F. Palacios, M.D. Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School Percutaneous transcatheter
More informationTranscatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
More informationPrince Sultan Cardiac Center Experience Riyadh, Saudi Arabia
Transcatheter Transapical Aortic Valve Implantation Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Ahmed Elwatidy, MD,PhD, FRCS S Kassab, MD,S Ahmari, MD, H Amri, MD, H Ismail, MD, A Calafiori,
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationBioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique
Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique Charanjit S. Rihal MD MBA Professor and Chair Division of Cardiovascular Diseases Mayo Clinic DISCLOSURES
More informationTranscatheter Pulmonary Valve Replacement Update on progress and outcomes
Transcatheter Pulmonary Valve Replacement Update on progress and outcomes Barry Love, MD Director, Congenital Cardiac Catheterization Laboratory Mount Sinai Medical Center New York, New York Transcatheter
More informationNeal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute
Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute Despite a 33 fold growth in the first five years, there is still tremendous variability among penetration in different countries
More informationSAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes
SAPIEN 3: Evaluation of a Balloon- Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis One-Year Outcomes Howard C. Herrmann, MD on behalf of The PARTNER II Trial
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationAustralia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes
Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationEstablishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
More informationTranscather Pulmonary Valve Replacement Using The Melody Valve: Indications, Techniques, Outcomes
Transcather Pulmonary Valve Replacement Using The Melody Valve: Indications, Techniques, Outcomes Matthew J. Gillespie MD The Children s Hospital of Philadelphia SCAI Fall Fellows Course 2014 December
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informationTranscatheter PV replacement: initial experience using selfexpandable
Transcatheter PV replacement: initial experience using selfexpandable valves. Alejandro Peirone MD, FSCAI Private and Children`s Hospital of Córdoba, Argentina. October 13th; Buenos Aires. Lecture title:
More informationUpdate on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center
Update on Percutaneous Therapies for Structural Heart Disease William Thomas MD Director of Structural Heart Program Tucson Medical Center NCVH 2014- Tucson Disclosure of Financial Interest Research: Stock
More information22/06/2017. Oxford City. Transcatheter aortic valve replacement 2017 guidelines. 1. First time I have heard about it. 2.
Oxford City Transcatheter aortic valve replacement 2017 guidelines Monday 19 th June Jim Newton Oxford Oxford University Hospitals NHS FT How familiar are you with TAVR? 1. First time I have heard about
More informationTranscatheter Therapies For Aortic Valve Disease. March 2017 Brian Whisenant MD
Transcatheter Therapies For Aortic Valve Disease March 2017 Brian Whisenant MD Introduction I got into this field to protect my turf. I must say, I have come full circle... - Kent W. Jones I got into this
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationTAVR: Echo Measurements Pre, Post And Intra Procedure
2017 ASE Florida, Orlando, FL October 10, 2017 8:00 8:25 AM 25 min TAVR: Echo Measurements Pre, Post And Intra Procedure Muhamed Sarić MD, PhD, MPA Director of Noninvasive Cardiology Echo Lab Associate
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationPercutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives. Bernard Iung Bichat Hospital, Paris
Percutaneous Treatment of Valvular Heart Diseases: Lessons and Perspectives Bernard Iung Bichat Hospital, Paris Euro Heart Survey on Valvular Diseases 3547 Patients with Native Valve Disease n= 1250 1000
More informationTAVI: Transapical Procedures
Cardiology Update Davos TAVI: Transapical Procedures Volkmar Falk, MD University Hospital Zürich TA-AVI: antegrade, simple, safe The front door approach! Transapical TAVI Technical advantages of TA approach
More informationTRANSCATHETER VALVE IMPLANTATION IN THE RIGHT HEART
TRANSCATHETER VALVE IMPLANTATION IN THE RIGHT HEART Dr Aphrodite Tzifa, MD(Res), FRCPCH Director, Paediatric and GUCH Cardiologist, Mitera Children's Hospital, Athens, Greece September 10, 2003 FAILURE
More informationProgress In Transcatheter Aortic Valve Implantation
Progress In Transcatheter Aortic Valve Implantation Gerald Yong MBBS (Hons) FRACP FSCAI Interventional Cardiologist Royal Perth Hospital Western Australia 4 th APCASH 8 th Sept 2013 Disclosure Statement
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informationValve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D.
Valve Replacement without a Scalpel Transcatheter Aortic Valve Replacement (TAVR) Charles T. Klodell, M.D. Professor, Thoracic and Cardiovascular Surgery University of Florida klodell@surgery.ufl.edu Disclosures
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationVascular complications of embolized core valve
Vascular complications of embolized core valve Suhail Dohad, MD FACC Director of Endovascular services, Interventional Cardiology Cardiovascular Research Foundation of Southern California, CVMG Director
More informationValvular Heart Disease and Adult Congenital Intervention. A Pichard, MD. Director Cath Labs, Washington Hospital Center. Georgetown University.
Valvular Heart Disease and Adult Congenital Intervention. A Pichard, MD Director Cath Labs, Washington Hospital Center. ProfessorofMedicine (Cardiology), Georgetown University. Conflict of Interest Proctor
More informationCoreValve Evolut R Technology review and Clinical Results. Paul TL Chiam
CoreValve Evolut R Technology review and Clinical Results Paul TL Chiam MBBS (S pore), MMed, MRCP (UK), FAMS FRCP (Edin), FESC (EU), FACC (USA), FSCAI (USA) Cardiologist Mount Elizabeth Hospital Singapore
More informationMulticentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system
Multicentre clinical study evaluating a novel resheatable self-expanding transcatheter aortic valve system Preliminary Results: Acute and 1-year Outcomes Ganesh Manoharan, MBBCh, MD, FRCP Consultant Cardiologist
More informationTAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
More informationHow Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, :00 11:25 PM 25 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ How Do I Evaluate a Patient Being Considered for TAVR? Sunday, February 14, 2016 11:00 11:25 PM 25 min 1 M U H A M E D S A R I Ć, M D, P H D
More informationTAVI: Nouveaux Horizons
TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationPolicy Specific Section: March 30, 2012 March 7, 2013
Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:
More informationAlternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy
Alternate Vascular Access for TAVR Gian Paolo Ussia Campus Bio-medico University, Rome Italy g.ussia@unicampus.it REQUIRED Gian Paolo Ussia I have no relevant financial relationships Transcatheter Valves
More informationNative Outflow Tract Transcatheter Pulmonary Valve Replacement
Native Outflow Tract Transcatheter Pulmonary Valve Replacement John P. Cheatham, MD, FSCAI George H. Dunlap Endowed Chair in Interventional Cardiology Co-Director, The Heart Center, Nationwide Children
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationTranscatheter Aortic Valve Implantation Management of risks and complications
Transcatheter Aortic Valve Implantation Management of risks and complications TAVI Summit, Seoul, Korea, Spetember 3rd, 2011 Alain Cribier University of Rouen, France Complications of TAVI Depending on
More information30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve. Didier Tchétché, MD On Behalf of the CENTERA Investigators
30-day Outcomes of The CENTERA Trial a New Self-Expanding Transcatheter Heart Valve Didier Tchétché, MD On Behalf of the CENTERA Investigators Speaker's name: Didier Tchétché, MD I have the following potential
More informationPercutaneous Valve Interventions. Percutaneous Valve Interventions
Percutaneous Valve Interventions Stanton J. Rowe President, Percutaneous Valve Interventions Edwards is Best Positioned to Capitalize on Percutaneous Valve Opportunities #1 global valve replacement and
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationAortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by
More informationΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012
ΔΙΑΔΕΡΜΙΚΗ ΑΝΣΙΚΑΣΑΣΑΗ ΑΟΡΣΙΚΗ ΒΑΛΒΙΔΑ αντιμετώπιση επιπλοκών ΠΕΣΡΟ. ΔΑΡΔΑ, MD, FESC IICE 2012 TAVR Technologies Current Generation Devices ~ 50,000 patients treated thru 2011 in > 500 interventional centers
More informationHardware in the Chest - From VADs to Valves
Hardware in the Chest - From VADs to Valves Cristina Fuss, MD Purpose Recognize the device Indication and function Cristina Fuss, MD Department of Diagnostic Radiology FROM VADS TO VALVES Implanting technique
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationHeart Team For TAVI Who and How?
2 nd TAVI Summit 2012, Seoul Corea Heart Team For TAVI Who and How? Alain Cribier, MD, Charles Nicolle Hospital University of Rouen, France Disclosure Edwards Lifesciences Consultant Training / proctoring
More informationInterventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504
Transcatheter valve-in-valve e implantation for aortic bioprosthetic valve dysfunction Interventional procedures guidance Published: 26 September 2014 nice.org.uk/guidance/ipg504 Your responsibility This
More informationTranscatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis
Transcatheter procedures of the future; expanding the treatment options for patients with severe aortic stenosis John Webb MD Director interventional cardiology, St Paul s Hospital McLeod Professor of
More informationNative Outflow Tract TranscatheterThe Heart Center Pulmonary Valve Replacement
Native Outflow Tract Transcatheter Pulmonary Valve Replacement John P. Cheatham, MD, FSCAI George H. Dunlap Endowed Chair in Interventional Cardiology Co-Director,, Nationwide Children s Hospital Professor,
More informationAortic Valve Stenosis and TAVR: Putting it all together.
Aortic Valve Stenosis and TAVR: Putting it all together. Maria L. Held, MSN CNS Valve Clinic Coordinator at The Cleveland Clinic Alliance of Cardiovascular Professionals April 14 th, 2018 Brief Anatomy
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationMinimalist Transcatheter Aortic Valve Replacement (MA-TAVR)
Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR) Jensen HA, Condado JF, Devireddy C, Binongo JN, Leshnower BG, Babaliaros V, Sarin EL, Lerakis S, Guyton RA, Stewart JP, Syed AQ, Mavromatis K,
More informationPercutaneous Therapy for Calcific Mitral Valve Disease
31 st Annual State of the Art Echocardiography San Diego, CA February 18, 2018 5:00 5:15 PM 15 min Percutaneous Therapy for Calcific Mitral Valve Disease Muhamed Sarić MD, PhD, MPA Director of Noninvasive
More informationTrans Catheter Aortic Valve Replacement
Trans Catheter Aortic Valve Replacement Satish K Surabhi, MD,FACC,FSCAI Medical Director, Cardiac Cath Labs AnMed Health Heart and Vascular Care No financial conflict of interest related to this talk Will
More informationTranscatheter Heart Valve Procedures
Medical Coverage Policy Transcatheter Heart Valve Procedures Table of Contents Coverage Policy... 1 Overview... 2 General Background... 2 Coding/Billing Information... 27 References... 29 Effective Date...11/15/2017
More informationOptimal Imaging Technique Prior to TAVI -Echocardiography-
2014 KSC meeting Optimal Imaging Technique Prior to TAVI -Echocardiography- Geu-Ru Hong, M.D. Ph D Associate Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University
More informationIan T. Meredith AM. MBBS, PhD, FRACP, FCSANZ, FACC, FAPSIC. Monash HEART, Monash Health & Monash University Melbourne, Australia
Two-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results From the REPRISE II
More informationTreatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques
Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques Pablo Codner, Abid Assali, Hanna Vaknin-Assa, Katia Orvin, Ram Sharony, Leor Perl, Gabriel Greenberg, Marina Kupershmidt,
More informationTranscatheter Aortic Valve Replacement with Evolut-R
Transcatheter Aortic Valve Replacement with Evolut-R Department of Transcatheter Heart Valves and 2 nd Cardiothoracic Surgery Clinic K. Spargias, M.Chrissoheris, A.Halapas, I. Nikolaou, S.Pattakos Disclosures
More informationDisclosures 4/16/2018. What s New in Valvularand Structural Heart Disease. None relevant to the presentation
What s New in Valvularand Structural Heart Disease Ryan C. Shelstad, MD Surgical Enthusiast, Valvular and Structural Heart Disease Bryan Heart Cardiothoracic Surgery Disclosures None relevant to the presentation
More informationNext Generations Native RVOT Valves
Ziyad M. Hijazi, MD, MPH, MSCAI, FACC Professor Of Pediatrics Weill Cornell Medical College Chair, Department of Pediatrics & Director, Sidra Cardiovascular Center of Excellence Doha-Qatar Disclosure:
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationFirst Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not Always
ISPUB.COM The Internet Journal of Cardiology Volume 9 Number 2 First Transfemoral Aortic Valve Implantation In Bulgaria - Crossing The Valve With The Device Is Not T D, J P. Citation T D, J P.. First Transfemoral
More informationPotential conflicts of interest
Potential conflicts of interest Speaker's name: Petros Dardas MEDTRONIC proctor for TAVI Intermediate risk 83 FEMALE COAD SEVERE AS NYHA III Mean gradient 35 mmhg, AVA 0.45cm2, SVI 21ml/m2 Paradoxical
More informationOutcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
More informationIncidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation
ESC Congress 2010 28 Aug 2010-01 Sep 2010 Stockholm - Sweden Incidence and Management of Early Implant Failure after Transcatheter Aortic Valve Implantation Gian Paolo Ussia, MD Director of Interventional
More informationTAVR: Review of the Robust Data from Randomized Trials
TAVR: Review of the Robust Data from Randomized Trials Nicholas J. Ruggiero II, MD,FACP, FACC, FSCAI, FSVM, FCPP Director, Structural Heart Disease and Non-Coronary Interventions Director, Jefferson Heart
More informationTranscatheter Aortic Valve Implantation Present Status and Perspectives
Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the
More information